Takao Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takao Watanabe has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Yoichi Hiasa
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City 791-0295, Japan
6 shared publications Atsushi Yukimoto
Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Toon Ehime Japan
4 shared publications- Masashi Hirooka
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
4 shared publications - Osamu Yoshida
Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Toon Ehime Japan
4 shared publications - Masanori Abe
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
3 shared publications - Yoshiko Nakamura
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
3 shared publications
Latest Publications
- 17 March 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (7) , 1079-1088
Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
Aim: We investigated whether the baseline fibrosis‐4 (FIB‐4) index stratifies long‐term cancer risk in patients with biopsy‐proven MASLD and compared its discrimination for HCC and extrahepatic malignancies against other noninvasive fibrosis markers. Methods: In this single‐center retrospective cohort study, 417 adults with biopsy‐proven MASLD (2001–2024) were followed for incident malignancy (median follow‐up, 4.75 years). Patients were categorized using standard FIB‐4 thresholds (< 1.3, 1.3–2.67, ≥ 2.67). Cause‐specific Cox models and Fine–Gray competing‐risk models were used to estimate adjusted hazard ratios (HRs) for HCC and extrahepatic cancer. Discriminative performance was evaluated using Harrell's C‐index and time‐dependent area under the curve (AUC) values at 3, 5, and 10 years. Results: During followup, 24 patients (5.8%) developed HCC, whereas 40 (9.6%) developed extrahepatic cancer. The ≥ 2.67 category was associated with markedly increased risks of HCC (adjusted HR 35.31) and extrahepatic cancer (adjusted HR 13.10) compared with < 1.3. Associations remained robust in competing‐risk and age‐adjusted sensitivity analyses. FIB‐4 showed the highest and most consistent discriminative performance among the evaluated indices (C‐indices of 0.83 for HCC and 0.78 for extrahepatic cancer). Time‐dependent AUCs improved over time and exceeded 0.80 for HCC after 5 years. Conclusion: The FIB‐4 index provides consistent long‐term risk stratification for HCC and shows an association with extrahepatic cancer among commonly used noninvasive fibrosis markers. Its strong time‐dependent discrimination for HCC and moderate discrimination for extrahepatic cancer support its potential role as a simple, widely accessible tool for long‐term risk stratification in MASLD.
- 17 March 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (7) , 1079-1088
Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
Aim: We investigated whether the baseline fibrosis‐4 (FIB‐4) index stratifies long‐term cancer risk in patients with biopsy‐proven MASLD and compared its discrimination for HCC and extrahepatic malignancies against other noninvasive fibrosis markers. Methods: In this single‐center retrospective cohort study, 417 adults with biopsy‐proven MASLD (2001–2024) were followed for incident malignancy (median follow‐up, 4.75 years). Patients were categorized using standard FIB‐4 thresholds (< 1.3, 1.3–2.67, ≥ 2.67). Cause‐specific Cox models and Fine–Gray competing‐risk models were used to estimate adjusted hazard ratios (HRs) for HCC and extrahepatic cancer. Discriminative performance was evaluated using Harrell's C‐index and time‐dependent area under the curve (AUC) values at 3, 5, and 10 years. Results: During followup, 24 patients (5.8%) developed HCC, whereas 40 (9.6%) developed extrahepatic cancer. The ≥ 2.67 category was associated with markedly increased risks of HCC (adjusted HR 35.31) and extrahepatic cancer (adjusted HR 13.10) compared with < 1.3. Associations remained robust in competing‐risk and age‐adjusted sensitivity analyses. FIB‐4 showed the highest and most consistent discriminative performance among the evaluated indices (C‐indices of 0.83 for HCC and 0.78 for extrahepatic cancer). Time‐dependent AUCs improved over time and exceeded 0.80 for HCC after 5 years. Conclusion: The FIB‐4 index provides consistent long‐term risk stratification for HCC and shows an association with extrahepatic cancer among commonly used noninvasive fibrosis markers. Its strong time‐dependent discrimination for HCC and moderate discrimination for extrahepatic cancer support its potential role as a simple, widely accessible tool for long‐term risk stratification in MASLD.
- Open Access
- 1 November 2022
- Published by Japan Society of Hepatology in Kanzo
- Vol. 63 (11) , 473-481
A case of alcohol-related liver cirrhosis diagnosed with thrombotic microangiopathy by renal biopsy
症例は70歳男性.アルコール性肝硬変の経過中にアルコール性肝炎を合併し入院した.血尿を伴うネフローゼ症候群を呈しており,禁酒,利尿剤と栄養療法の導入により蛋白尿は改善した.顕微鏡的血尿が残存したため腎生検を実施し,血栓性微小血管障害症(TMA)と診断した.血漿ADAMTS13活性低下とvon Willebrand factor(VWF)抗原高値がみられ,肝星細胞減少によるADAMTS13産生低下がTMAの原因と想定された.ADAMTS13補充目的に新鮮凍結血漿(FFP)の投与,内皮細胞障害に対してトロンボモジュリン製剤(rTM)を開始した.FFPの漸減,中止後もADAMTS13活性の低下はみられず,腎機能が維持された.肝硬変の経過中に血尿が出現した場合,ADAMTS13活性低下とVWF抗原とのインバランスがある場合はTMAを疑い,FFPやrTMの投与を考慮する必要があると考えられた.
- 1 November 2022
- Published by Japan Society of Hepatology in Kanzo
- Vol. 63 (11) , 473-481
Open AccessA case of alcohol-related liver cirrhosis diagnosed with thrombotic microangiopathy by renal biopsy
症例は70歳男性.アルコール性肝硬変の経過中にアルコール性肝炎を合併し入院した.血尿を伴うネフローゼ症候群を呈しており,禁酒,利尿剤と栄養療法の導入により蛋白尿は改善した.顕微鏡的血尿が残存したため腎生検を実施し,血栓性微小血管障害症(TMA)と診断した.血漿ADAMTS13活性低下とvon Willebrand factor(VWF)抗原高値がみられ,肝星細胞減少によるADAMTS13産生低下がTMAの原因と想定された.ADAMTS13補充目的に新鮮凍結血漿(FFP)の投与,内皮細胞障害に対してトロンボモジュリン製剤(rTM)を開始した.FFPの漸減,中止後もADAMTS13活性の低下はみられず,腎機能が維持された.肝硬変の経過中に血尿が出現した場合,ADAMTS13活性低下とVWF抗原とのインバランスがある場合はTMAを疑い,FFPやrTMの投与を考慮する必要があると考えられた.
- 24 December 2020
- Published by Wiley in Hepatology Research
- Vol. 51 (3) , 284-293
Dilatation of lymphatic vessels increases liver stiffness on transient elastography irrespective of fibrosis
Aim: Liver stiffness measured using transient elastography (TE) is affected by tissue viscosity. The role of intrahepatic lymphatic fluid in liver stiffness is unclear. The present study aimed to investigate the effects of lymphatic vessel dilatation on liver stiffness.Methods: Patients with chronic liver disease (n = 116) were enrolled from June 2018 to March 2020. All specimens were acquired by laparoscopic liver biopsy. Biopsy samples were stained with D2‐40 for lymphatic vessel quantification based on a five‐point scale for each specimen. Independent associations of liver stiffness measured by TE, strain elasticity (liver fibrosis index), and controlled attenuation parameter with fibrosis, lymphatic vessels, alanine aminotransferase, bilirubin, and steatosis were evaluated.Results: Fibrosis, splenic stiffness measurement, and splenic volume were significantly correlated with the area of lymphatic vessels. Fibrosis, lymphatic vessels, and alanine aminotransferase were independent factors significantly associated with liver stiffness measurement (LSM; standardized coefficient [β] = 0.375, P < 0.001; β = 0.342, P < 0.001; and β = 0.359, P < 0.001, respectively). Fibrosis was the only independent factor significantly associated with liver fibrosis index (β = 0.360, P < 0.001), whereas the fat deposit area was the only independent factor significantly associated with controlled attenuation parameter (β = 0.455, P < 0.001). The areas under the receiver operating characteristic curves for diagnosing controlled ascites based on LSM, liver fibrosis index, splenic stiffness measurement, collagen proportionate area, and area of lymphatic vessels were 0.94, 0.66, 0.76, 0.64, and 0.79, respectively.Conclusions: Lymphatic vessel dilatation can affect liver stiffness measured using TE. Liver stiffness measurement is a predictive factor for ascites.
- 24 December 2020
- Published by Wiley in Hepatology Research
- Vol. 51 (3) , 284-293
Dilatation of lymphatic vessels increases liver stiffness on transient elastography irrespective of fibrosis
Aim: Liver stiffness measured using transient elastography (TE) is affected by tissue viscosity. The role of intrahepatic lymphatic fluid in liver stiffness is unclear. The present study aimed to investigate the effects of lymphatic vessel dilatation on liver stiffness.Methods: Patients with chronic liver disease (n = 116) were enrolled from June 2018 to March 2020. All specimens were acquired by laparoscopic liver biopsy. Biopsy samples were stained with D2‐40 for lymphatic vessel quantification based on a five‐point scale for each specimen. Independent associations of liver stiffness measured by TE, strain elasticity (liver fibrosis index), and controlled attenuation parameter with fibrosis, lymphatic vessels, alanine aminotransferase, bilirubin, and steatosis were evaluated.Results: Fibrosis, splenic stiffness measurement, and splenic volume were significantly correlated with the area of lymphatic vessels. Fibrosis, lymphatic vessels, and alanine aminotransferase were independent factors significantly associated with liver stiffness measurement (LSM; standardized coefficient [β] = 0.375, P < 0.001; β = 0.342, P < 0.001; and β = 0.359, P < 0.001, respectively). Fibrosis was the only independent factor significantly associated with liver fibrosis index (β = 0.360, P < 0.001), whereas the fat deposit area was the only independent factor significantly associated with controlled attenuation parameter (β = 0.455, P < 0.001). The areas under the receiver operating characteristic curves for diagnosing controlled ascites based on LSM, liver fibrosis index, splenic stiffness measurement, collagen proportionate area, and area of lymphatic vessels were 0.94, 0.66, 0.76, 0.64, and 0.79, respectively.Conclusions: Lymphatic vessel dilatation can affect liver stiffness measured using TE. Liver stiffness measurement is a predictive factor for ascites.
- Open Access
- 30 January 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Depletion of B cell-activating factor attenuates hepatic fat accumulation in a murine model of nonalcoholic fatty liver disease
Obesity-induced adipose-tissue dysfunction is a critical contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). B cell-activating factor (BAFF) is an adipokine related to impaired insulin sensitivity, and the serum BAFF concentration is associated with NAFLD severity. In this study, we aimed to determine the direct in vivo role of BAFF in the development of insulin resistance, adipocyte dysfunction, and hepatic steatosis using BAFF−/− mice fed a high-fat diet (HFD). HFD-fed BAFF−/− mice exhibited significantly improved insulin sensitivity despite their increased weight gain and adiposity relative to HFD-fed wild-type mice. Moreover, inflammation, especially the accumulation of CD11c+ adipose-tissue macrophages, and fibrosis of epididymal adipose tissue were reduced, contributing to healthy adipose-tissue expansion in obese BAFF−/− mice. In line with metabolically healthy obesity, hepatic steatosis also decreased, and we observed attenuated de novo lipogenesis in both the livers and hepatocytes of BAFF−/− mice. Our data revealed that BAFF serves as a potential stimulator of unhealthy adipose-tissue expansion by triggering inflammation and fibrosis and ultimately leading to enhanced insulin resistance and NAFLD. Therefore, these results suggest that BAFF is a promising target for diabetes and NAFLD treatment.
- 30 January 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Open AccessDepletion of B cell-activating factor attenuates hepatic fat accumulation in a murine model of nonalcoholic fatty liver disease
Obesity-induced adipose-tissue dysfunction is a critical contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). B cell-activating factor (BAFF) is an adipokine related to impaired insulin sensitivity, and the serum BAFF concentration is associated with NAFLD severity. In this study, we aimed to determine the direct in vivo role of BAFF in the development of insulin resistance, adipocyte dysfunction, and hepatic steatosis using BAFF−/− mice fed a high-fat diet (HFD). HFD-fed BAFF−/− mice exhibited significantly improved insulin sensitivity despite their increased weight gain and adiposity relative to HFD-fed wild-type mice. Moreover, inflammation, especially the accumulation of CD11c+ adipose-tissue macrophages, and fibrosis of epididymal adipose tissue were reduced, contributing to healthy adipose-tissue expansion in obese BAFF−/− mice. In line with metabolically healthy obesity, hepatic steatosis also decreased, and we observed attenuated de novo lipogenesis in both the livers and hepatocytes of BAFF−/− mice. Our data revealed that BAFF serves as a potential stimulator of unhealthy adipose-tissue expansion by triggering inflammation and fibrosis and ultimately leading to enhanced insulin resistance and NAFLD. Therefore, these results suggest that BAFF is a promising target for diabetes and NAFLD treatment.
- 18 October 2018
- Published by Wiley in Hepatology Research
- Vol. 49 (2) , 136-146
Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection
Aim: The predictors for the development of hepatocellular carcinoma (HCC) after direct‐acting antiviral (DAA) treatment were investigated.Methods: A total of 1174 patients with chronic hepatitis C virus infection were treated with DAA therapy (sofosbuvir and ledipasvir [n = 615], sofosbuvir and ribavirin [n = 380], and daclatasvir and asunaprevir [n = 179]) and achieved sustained virologic response (SVR). The HCC development rate and the factors that might contribute to the development of HCC after the end of DAA treatment were analyzed.Results: During the median observation period of 537 days, HCC developed in 33 cases. The incidence of HCC was 1.9%, 3.2%, and 4.1% at 1, 1.5, and 2 years after the end of DAA therapy, respectively. Multivariate analysis with pre‐ and post‐treatment factors identified the Fibrosis‐4 (FIB‐4) index (hazard ratio [HR] = 1.09; 95% confidence interval [CI], 1.021–1.178; P = 0.011) and post‐treatment α‐fetoprotein (AFP) (HR = 1.11; 95% CI, 1.054–1.172; P < 0.001) as independent factors that contributed to the development of HCC after DAA therapy. Using these identified parameters, a new scoring system (0 to 2 points) was established. Patients in the high‐score group (2 points) could be identified as having a significantly higher risk of HCC development, and the respective 1‐ and 2‐year cumulative incidence rates of HCC were 6.1% and 14.4%.Conclusions: A high FIB‐4 index and a high post‐treatment AFP at the end of DAA treatment were the independent predictors for developing HCC after DAA treatment. For patients with these risk factors, extra attention to the possibility of HCC development is needed.
- 18 October 2018
- Published by Wiley in Hepatology Research
- Vol. 49 (2) , 136-146
Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection
Aim: The predictors for the development of hepatocellular carcinoma (HCC) after direct‐acting antiviral (DAA) treatment were investigated.Methods: A total of 1174 patients with chronic hepatitis C virus infection were treated with DAA therapy (sofosbuvir and ledipasvir [n = 615], sofosbuvir and ribavirin [n = 380], and daclatasvir and asunaprevir [n = 179]) and achieved sustained virologic response (SVR). The HCC development rate and the factors that might contribute to the development of HCC after the end of DAA treatment were analyzed.Results: During the median observation period of 537 days, HCC developed in 33 cases. The incidence of HCC was 1.9%, 3.2%, and 4.1% at 1, 1.5, and 2 years after the end of DAA therapy, respectively. Multivariate analysis with pre‐ and post‐treatment factors identified the Fibrosis‐4 (FIB‐4) index (hazard ratio [HR] = 1.09; 95% confidence interval [CI], 1.021–1.178; P = 0.011) and post‐treatment α‐fetoprotein (AFP) (HR = 1.11; 95% CI, 1.054–1.172; P < 0.001) as independent factors that contributed to the development of HCC after DAA therapy. Using these identified parameters, a new scoring system (0 to 2 points) was established. Patients in the high‐score group (2 points) could be identified as having a significantly higher risk of HCC development, and the respective 1‐ and 2‐year cumulative incidence rates of HCC were 6.1% and 14.4%.Conclusions: A high FIB‐4 index and a high post‐treatment AFP at the end of DAA treatment were the independent predictors for developing HCC after DAA treatment. For patients with these risk factors, extra attention to the possibility of HCC development is needed.
- Open Access
- 25 February 2018
- Published by Wiley in Cancer Science
- Vol. 109 (4) , 919-925
Roles of protein kinase R in cancer: Potential as a therapeutic target
Double‐stranded (ds) RNA‐dependent protein kinase (PKR) is a ubiquitously expressed serine/threonine protein kinase. It was initially identified as an innate immune antiviral protein induced by interferon (IFN) and activated by dsRNA. PKR is recognized as a key executor of antiviral host defense. Moreover, it contributes to inflammation and immune regulation through several signaling pathways. In addition to IFN and dsRNA, PKR is activated by multiple stimuli and regulates various signaling pathways including the mitogen‐activated protein kinase (MAPK) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells pathways. PKR was initially thought to be a tumor suppressor as a result of its ability to suppress cell growth and interact with major tumor suppressor genes. However, in several types of malignant disease, such as colon and breast cancers, its role remains controversial. In hepatocellular carcinoma, hepatitis C virus (HCV) is the main cause of liver cancer, and PKR inhibits HCV replication, indicating its role as a tumor suppressor. However, PKR is overexpressed in cirrhotic patients, and acts as a tumor promoter through enhancement of cancer cell growth by mediating MAPK or signal transducer and activator of transcription pathways. Moreover, PKR is reportedly required for the activation of inflammasomes and influences metabolic disorders. In the present review, we introduce the multifaceted roles of PKR such as antiviral function, tumor cell growth, regulation of inflammatory immune responses, and maintaining metabolic homeostasis; and discuss future perspectives on PKR biology including its potential as a therapeutic target for liver cancer.
- 25 February 2018
- Published by Wiley in Cancer Science
- Vol. 109 (4) , 919-925
Open AccessRoles of protein kinase R in cancer: Potential as a therapeutic target
Double‐stranded (ds) RNA‐dependent protein kinase (PKR) is a ubiquitously expressed serine/threonine protein kinase. It was initially identified as an innate immune antiviral protein induced by interferon (IFN) and activated by dsRNA. PKR is recognized as a key executor of antiviral host defense. Moreover, it contributes to inflammation and immune regulation through several signaling pathways. In addition to IFN and dsRNA, PKR is activated by multiple stimuli and regulates various signaling pathways including the mitogen‐activated protein kinase (MAPK) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells pathways. PKR was initially thought to be a tumor suppressor as a result of its ability to suppress cell growth and interact with major tumor suppressor genes. However, in several types of malignant disease, such as colon and breast cancers, its role remains controversial. In hepatocellular carcinoma, hepatitis C virus (HCV) is the main cause of liver cancer, and PKR inhibits HCV replication, indicating its role as a tumor suppressor. However, PKR is overexpressed in cirrhotic patients, and acts as a tumor promoter through enhancement of cancer cell growth by mediating MAPK or signal transducer and activator of transcription pathways. Moreover, PKR is reportedly required for the activation of inflammasomes and influences metabolic disorders. In the present review, we introduce the multifaceted roles of PKR such as antiviral function, tumor cell growth, regulation of inflammatory immune responses, and maintaining metabolic homeostasis; and discuss future perspectives on PKR biology including its potential as a therapeutic target for liver cancer.
- 1 April 2013
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 48 (4) , 782-788
Non-promoter DNA hypermethylation of Zygote Arrest 1 (ZAR1) in neuroblastomas
- 1 April 2013
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 48 (4) , 782-788
Non-promoter DNA hypermethylation of Zygote Arrest 1 (ZAR1) in neuroblastomas
- 1 June 2011
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (6) , 1031-1038
Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments
The present study investigated prediction of the overall renal tubular secretion and hepatic clearances of anionic drugs based on in vitro transport studies. The saturable uptake of eight drugs, most of which were OAT3 substrates (rosuvastatin, pravastatin, pitavastatin, valsartan, olmesartan, trichlormethiazide, p-aminohippurate, and benzylpenicillin) by freshly prepared human kidney slices underestimated the overall intrinsic clearance of the tubular secretion; therefore, a scaling factor of 10 was required for in vitro-in vivo extrapolation. We examined the effect of gemfibrozil and its metabolites, gemfibrozil glucuronide and the carboxylic metabolite, gemfibrozil M3, on pravastatin uptake by human kidney slices. The inhibition study using human kidney slices suggests that OAT3 plays a predominant role in the renal uptake of pravastatin. Comparison of unbound concentrations and Ki values (1.5, 9.1, and 4.0 μM, for gemfibrozil, gemfibrozil glucuronide, and gemfibrozil M3, respectively) suggests that the mechanism of the interaction is due mainly to inhibition by gemfibrozil and gemfibrozil glucuronide. Furthermore, extrapolation of saturable uptake by cryopreserved human hepatocytes predicts clearance comparable with the observed hepatic clearance although fluvastatin and rosuvastatin required a scaling factor of 11 and 6.9, respectively. This study suggests that in vitro uptake assays using human kidney slices and hepatocytes provide a good prediction of the overall tubular secretion and hepatic clearances of anionic drugs and renal drug-drug interactions. It is also recommended that in vitro-in vivo extrapolation be performed in animals to obtain more reliable prediction.
- 1 June 2011
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (6) , 1031-1038
Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments
The present study investigated prediction of the overall renal tubular secretion and hepatic clearances of anionic drugs based on in vitro transport studies. The saturable uptake of eight drugs, most of which were OAT3 substrates (rosuvastatin, pravastatin, pitavastatin, valsartan, olmesartan, trichlormethiazide, p-aminohippurate, and benzylpenicillin) by freshly prepared human kidney slices underestimated the overall intrinsic clearance of the tubular secretion; therefore, a scaling factor of 10 was required for in vitro-in vivo extrapolation. We examined the effect of gemfibrozil and its metabolites, gemfibrozil glucuronide and the carboxylic metabolite, gemfibrozil M3, on pravastatin uptake by human kidney slices. The inhibition study using human kidney slices suggests that OAT3 plays a predominant role in the renal uptake of pravastatin. Comparison of unbound concentrations and Ki values (1.5, 9.1, and 4.0 μM, for gemfibrozil, gemfibrozil glucuronide, and gemfibrozil M3, respectively) suggests that the mechanism of the interaction is due mainly to inhibition by gemfibrozil and gemfibrozil glucuronide. Furthermore, extrapolation of saturable uptake by cryopreserved human hepatocytes predicts clearance comparable with the observed hepatic clearance although fluvastatin and rosuvastatin required a scaling factor of 11 and 6.9, respectively. This study suggests that in vitro uptake assays using human kidney slices and hepatocytes provide a good prediction of the overall tubular secretion and hepatic clearances of anionic drugs and renal drug-drug interactions. It is also recommended that in vitro-in vivo extrapolation be performed in animals to obtain more reliable prediction.
- Open Access
- 1 January 1996
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 180 (1) , 1-15
Chronological Changes and Inter-Regional Differences in Dietary Fiber Intakes among Middle-Aged Japanese Women.
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 1996
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 180 (1) , 1-15
Open AccessChronological Changes and Inter-Regional Differences in Dietary Fiber Intakes among Middle-Aged Japanese Women.
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies